Bristol Myers Squibb

Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients |

www.fiercepharma.com | As one of many hottest markets in prescribed drugs, immunology has grow to be a murderers’ row of blockbuster medication in recent times. However Bristol Myers Squibb has huge hopes for a next-gen entry in Zeposia, and it is angling for a foothold in ulcerative colitis to get …

Read More

Brown's Returns Beat the Big Boys of the Ivy League

www.barrons.com | Brown's fund had an uncommon combine: 37% was in non-public fairness, 37% in absolute return (normally hedge funds), and 14% in shares. The remainder was in actual …

Read More

error:
Scroll to Top